13 reports

  • PFIZER IN GLOBAL FACTOR VIII MARKET
  • BAYER HEALTHCARE IN GLOBAL FACTOR VIII MARKET

About Factor VIII Factor VIII is an essential blood-clotting protein, which is also known as an antihemophilic factor. In individuals, factor VIII is encoded by F8 gene. Defects in F8 gene lead to hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is generated in liver sinusoidal cells and endothelial cells...

  • Factor VIII
  • Baxalta Incorporated
  • Bayer AG
  • Biogen Idec Inc.
  • Grifols, S.A.

Factor VIII Sales, Price Analysis, & Sales Forecast - 2017 ##.

  • Biopharmaceutical
  • Factor VIII
  • World
  • Demand

Factor VIII Inhibitor Bypassing Fraction Sales, Price Analysis, & Sales Forecast - 2017 ##.

  • Biopharmaceutical
  • Factor VIII
  • World
  • Demand

Factor VIII / Von Willebrand factor Sales, Price Analysis, & Sales Forecast - 2017 ##.

  • Biopharmaceutical
  • Factor VIII
  • World
  • Demand
  • 2.9 Global Factor VIII Market
  • 2.9 Global Factor VIII Market

Plasma forms 50% of the composition of blood in humans. Blood plasma is crucial because it is composed of different proteins. These plasma proteins or derivatives are extracted via a process known as fractionation. These proteins have high therapeutic value because they are used in several indications and its new uses...

  • Factor VIII
  • World
  • CSL Limited
  • Grifols, S.A.
  • Shire plc
  • Gene therapy to activate factor IX for hemophilia B
  • 2.9.4 GENE THERAPY

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia is a rare disease affecting more than 400,000 people worldwide. Hemophilia A is four to six times as common as...

  • Factor VIII
  • World
  • CSL Behring GmbH
  • Novo Nordisk Group
  • Pfizer Inc.
  • Clinical Trial profile. 145 Trial Title
  • Clinical Trial profile. 55 Trial Title

Hemophilia A Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Hemophilia A Global Clinical Trials Review, H2, 2017" provides an overview of Hemophilia A clinical trials scenario. This report provides top line data relating to the clinical trials on Hemophilia A. Report includes an...

  • Factor VIII
  • World
  • Bayer AG
  • Novo Nordisk Group
  • Octapharma AG

(China) ##.

  • Biochemical
  • Blood Supply
  • Factor VIII
  • China
  • Market Shares
  • Proportion of Von Willebrand Disease (Factor VIII Deficiency) to Hematological Disorders Clinical Trials, G7 Countries
  • Proportion of Von Willebrand Disease (Factor VIII Deficiency) to Hematological Disorders Clinical Trials, E7 Countries

Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Von Willebrand Disease (Factor VIII Deficiency) Global Clinical Trials Review, H2, 2016" provides an overview of Von Willebrand Disease (Factor VIII Deficiency) clinical trials scenario....

  • Blood Disease
  • Factor VIII
  • Therapy
  • World
  • Product Initiative

Von Willebrand Disease (Factor VIII Deficiency) Ongoing Global Clinical Trials Analysis and Outlook ## Table of Contents ##. ## List of Figures ##. ## List of Tables ## Key Findings, 2018 ##. ## Snapshot ##. ## Overview of Von Willebrand Disease (Factor VIII Deficiency

  • Biopharmaceutical
  • Clinical Trial
  • Drug Discovery And Development
  • Factor VIII
  • MEAN PER CAPITA USAGE OF FACTOR VIII (2016)
  • FACTOR VIII OFFERED BY KEY MARKET PLAYERS

The plasma fractionation market is projected to reach to USD 29.50 billion by 2023 from an estimated USD 21.23 billion in 2018. The growing geriatric population across the globe, increasing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and uptake of alpha-1-antitrypsin, and increase in plasma...

  • Factor VIII
  • North America
  • United States
  • Market Size
  • Grifols, S.A.
  • RECOMBINANT FACTOR VIII REPLACEMENT FOR HEMOPHILIA A - DRUG PROFILE
  • GENE THERAPY TO ACTIVATE FACTOR VIII FOR HEMOPHILIA A - DRUG PROFILE

Hemophilia A - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape. Hemophilia A is an X-linked, recessive...

  • Blood Disease
  • Factor VIII
  • United States
  • Company
  • Product Initiative
  • RECOMBINANT FACTOR VIII REPLACEMENT FOR HEMOPHILIA A - DRUG PROFILE
  • RECOMBINANT PROTEIN TO TARGET COAGULATION FACTOR VIII FOR HEMOPHILIA A - DRUG PROFILE

Hemophilia A - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H1 2018, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape. Hemophilia A is an X-linked, recessive...

  • Blood Disease
  • Factor VIII
  • United States
  • World
  • Alnylam Pharmaceuticals, Inc.